Gli altri portali
Notizie
Comunicati Stampa
Social News
Offerte di Lavoro
Comunicati Stampa
Sezioni
Toggle navigation
Prima pagina
Elenco
Nuovo account
Inserimento
Pannello di controllo
Modifica password
Salute e Benessere
Seleziona Categoria
Tutte le Categorie
Agricoltura
Ambiente
Arte e Cultura
Cibi e Bevande
Economia
Editoria e Media
Elettronica
Energia
Fiere ed Eventi
Industria
Information Technology
Internet
Istruzione e Formazione
Moda
Non Profit
Politica e Istituzioni
Salute e Benessere
Scienza e Tecnologia
Servizi
Società
Spettacolo
Sport
Telecomunicazioni
Trasporti
Turismo
Varie
Italiano
Inglese
Spagnolo
Global Short-Acting Insulin Market is Expected to Cross ~USD 9 Billion by 2030 |…
Key Takeaways from the Short-Acting Insulin Market Report Key Takeaways from the Short-Acting Insulin Market Report To read more about the latest highlights related to the short-acting insulin market, get a snapshot of the key highlights entailed in the Global Short-Acting Insulin Market Report Short-Acting Insulin Overview Short-acting insulin is designed to manage blood glucose levels by mimicking the body's natural insulin response. This type of insulin begins to work within...
PR Newswire
05/09/2024
Global Nuclear Magnetic Resonance Spectroscopy Market is Predicted to Grow at a…
Key Takeaways from the Nuclear Magnetic Resonance Spectroscopy Market Report Key Takeaways from the Nuclear Magnetic Resonance Spectroscopy Market Report To read more about the latest highlights related to the NMR market, get a snapshot of the key highlights entailed in the Global Nuclear Magnetic Resonance Spectroscopy Market Report Nuclear Magnetic Resonance Spectroscopy Overview Nuclear magnetic resonance (NMR) spectroscopy is a powerful analytical technique used to...
PR Newswire
05/09/2024
Nyxoah to Participate in Upcoming Investor Conferences
Nyxoah to Participate in Upcoming Investor ConferencesMont-Saint-Guibert, Belgium – September 5, 2024, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)(“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will participate in three upcoming investor conferences in New York City. Olivier Taelman, Nyxoah's Chief...
Nasdaq GlobeNewswire
05/09/2024
Asgard Therapeutics' study published in Science showing proof-of-concept and…
Publication of the study follows Asgard's €30 million Series A financing to advance its cell reprogramming platform, as the Company continues to make significant progress in preparing AT-108 for clinical development. Asgard recently commenced activities to establish CMC process for scale-up manufacturing of GMP-grade AT-108 for Phase I/II trials. Publication of the study follows Asgard's €30 million Series A financing to advance its cell reprogramming platform, as the Company continues to…
PR Newswire
05/09/2024
Vivoryon Therapeutics N.V. Announces Completion of Share Capital Reduction and…
Vivoryon Therapeutics N.V. Announces Completion of Share Capital Reduction and Change to Articles of AssociationHalle (Saale) / Munich, Germany, September 5, 2024- Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) ( Vivoryon,or the Company ), a clinical stage company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, today announced that it has completed the reduction of...
Nasdaq GlobeNewswire
05/09/2024
Report of transactions of shares and related securities of Bavarian Nordic by…
COPENHAGEN, Denmark, September 5, 2024– Bavarian Nordic A/S (OMX: BAVA) has today received information about the following transactions of the company's shares/related securities by persons holding managerial responsibilities and/or persons/companies closely associated with such. 1.Details of the person discharging managerial responsibilities/person closely associated a)NamePaul John Chaplin 2.Reason for the notification a)Position/statusPresident and Chief...
Nasdaq GlobeNewswire
05/09/2024
Rising Chronic Kidney Disease Prevalence Sparks Global Dialysis Market Growth
by End-Use by End-Use by Region Get your Sample PDF:https://www.maximizemarketresearch.com/request-sample/80725/ Embracing Digital Innovations and Revolutionary Technologies The dialysis market is being transformed by digital advancements and innovations, creating a significant boost in its growth potential.Telemedicine, remote monitoring, and wearable devices are revolutionizing patient care, making it more efficient and accessible. In remote areas, telemedicine...
PR Newswire
05/09/2024
New data on aprocitentan to be presented at the AHA Hypertension Scientific…
Two abstracts win the prestigious AHA 2024 Paul Dudley White International Scholar AwardAllschwil, Switzerland – September 5, 2024Idorsia Ltd (SIX: IDIA) today announced that new data on aprocitentan, Idorsia's endothelin receptor antagonist, will be presented at the American Heart Association (AHA) Hypertension Scientific Sessions 2024, taking place in Chicago, Illinois, September 5–8, 2024. On March 19, 2024, aprocitentan was approved as TRYVIO™ in the US, with availability planned...
Nasdaq GlobeNewswire
05/09/2024
Boehringer Ingelheim announces plans to advance potential new treatment for…
Ingelheim, Germany and Basel, Switzerland, September 5, 2024 – Boehringer Ingelheim and CDR-Life today announce positive results from the Phase I evaluation of BI 771716 (Study Record | ClinicalTrials.gov), an investigational antibody fragment developed to preserve vision in people living with geographic atrophy (GA). BI 771716 met its primary safety endpoint following intravitreal administration of single and multiple doses. Preparation for the Phase II trial is now underway, with an...
Nasdaq GlobeNewswire
05/09/2024
BIZCLIK MEDIA LAUNCHES SEPTEMBER EDITION OF HEALTHCARE DIGITAL
Healthcare Digital Healthcare Digital This month's edition includes an extensive lead feature with leading experts and executives from Oklahoma Cancer Specialists & Research Institute on transforming operations with GE Healthcare. "The addition of the zero-footprint viewer is fantastic for sharing images with outside physicians and providers who mutually care for patients. We can share images without granting access to our system, which is significant for security" -Jennifer...
PR Newswire
05/09/2024
Surgical Robots Market to Surge from USD 11.1 Billion to USD 23.7 Billion by…
Browse in-depth TOC on "Surgical Robots Market" Browse in-depth TOC on "Surgical Robots Market" 355 - Tables59 - Figures319 - Pages Market Segmentation by Offering The surgical robots market is categorized into instruments & accessories, robotic systems, and services. In 2023, the instruments and accessories segment is projected to dominate the market. These components are essential for enhancing the functionality, precision, and flexibility of robotic surgical...
PR Newswire
05/09/2024
Maxima Grupė's First Half of 2024: Moderate Revenue Growth due to Lower Product…
In the first half of 2024, the consolidated revenue of the companies managed by MAXIMA GRUPĖ, UAB increased by 4.7% compared to the same period last year, reaching €3 billion . The most significant contributors to this growth were ongoing expansion in Poland and Bulgaria, as well as increased sales in Lithuania and Latvia. Like-for-like (LFL) retail sales revenues, calculated at a constant exchange rate, grew by 2.2%. The overall revenue growth of the Group in the first half of this...
Nasdaq GlobeNewswire
05/09/2024
Phagenesis Appoints Chad Hoskins as Chief Executive Officer Following Recent…
The company previously announced it closed $42M in Series D financing, led by EQT Life Sciences and Sectoral Asset Management, with new investors British Patient Capital, Northern Gritstone and Aphelion. The funding is primarily intended to bolster commercialization efforts for Phagenyx® in the US and Europe. Phagenyx® is the first and only pharyngeal electrical stimulation (PES) therapy that directly treats neurogenic dysphagia (difficulty swallowing), which is most often caused by stroke. Each…
PR Newswire
05/09/2024
Roborock Unveils World-First Smart Home Cleaning Technologies, Redefining the…
Roborock Qrevo Curv and Qrevo Edge: Setting New Standards with Industry-First AdaptiLift Chassis and Revolutionary Dual Anti-Tangle System Roborock Qrevo Curv and Qrevo Edge: Setting New Standards with Industry-First AdaptiLift Chassis and Revolutionary Dual Anti-Tangle System Roborock Qrevo Curv and Qrevo Edge introduce an industry-first innovation, the AdaptiLift Chassis, which incorporate an independently adjustable three-wheel control (left and right main wheels, and...
PR Newswire
05/09/2024
Andrew MacGarvey & Conditor Capital launch Coronado Research to maximise the use…
Sachin Korantak of Conditor Capital led the investment process, adding Coronado Research to a portfolio already positioned in the pre-clinical space. Sachin Korantak of Conditor Capital led the investment process, adding Coronado Research to a portfolio already positioned in the pre-clinical space. Korantak commented, "Conditor are very impressed with the vision set out by the Coronado team. Andrew has a deep understanding of how data can be used to optimise clinical development and a...
PR Newswire
05/09/2024
Tier-One Canadian Life and Health Insurance Carrier Selects Sapiens Insurance…
Sapiens Insurance Platform will be instrumental in enabling a client-first approach from the first touch point during new business to continued service excellence and administration, including enhanced support for their distribution channels, simplifying the business rules for an easier and proactive engagement, and continued enhanced support for the customer throughout their life events. This will be further enabled through simplified product development and management capabilities, a…
PR Newswire
05/09/2024
First Doses of Bavarian Nordic's Mpox Vaccine Now Arriving in the Democratic…
Vaccine donations from the European Commission, the U.S. government and Bavarian Nordic are now entering the DRC, the epicenter of the mpox outbreakMore than 250,000 doses to arrive over the next week, marking a crucial turning point in the combat against mpox in AfricaCOPENHAGEN, Denmark, September 5, 2024– Bavarian Nordic A/S (OMX: BAVA) announced today that the first doses of its mpox vaccine, MVA-BN ®, also known as JYNNEOS ®, has arrived today in the Democratic Republic of...
Nasdaq GlobeNewswire
05/09/2024
BioNTech to Present Clinical Data Updates Across mRNA and Immunomodulatory…
MAINZ, Germany, September 05, 2024– BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present clinical trial data for selected assets from its multi-platform oncology pipeline at the European Society for Molecular Oncology (“ESMO”) Congress 2024 in Barcelona, Spain from September 13-17, 2024. The oral and poster presentations will feature programs across BioNTech's clinical pipeline, including mRNA-based cancer vaccines, next-generation immunomodulators and targeted therapy...
Nasdaq GlobeNewswire
05/09/2024
Major shareholder announcement
Pursuant to Section 30 of the Danish Capital Markets Act, Novonesis hereby announces that BlackRock, Inc. has notified Novonesis of the following status relating to the position of share capital attached to shares and share capital through financial instruments.Per September 2, 2024, BlackRock, Inc. has adjusted its holding of shares to an equivalent of 23,377,683 shares, corresponding to 4.99% (previously 5.12%) of the total share capital attached to shares. The combined total of share...
Nasdaq GlobeNewswire
05/09/2024
OKYO Pharma Announces Chairman Acquires Shares
LONDON and NEW YORK, Sept.05, 2024(GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA approved therapy, announced today that it has been notified that Panetta Partners Limited, an...
Nasdaq GlobeNewswire
05/09/2024
Tube Packaging Market worth $4.6 Billion by 2029 - Exclusive Report by…
Browse in-depth TOC on "Tube Packaging Market". Browse in-depth TOC on "Tube Packaging Market". 368 – Tables 55 – Figures 279 – Pages Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=128857249 "By Type, Laminated accounted for the second-largest market share in 2023." Laminated accounted for the largest share among different types in the Tube packaging market. Laminated tubes offer superior barrier protection as compared to...
PR Newswire
05/09/2024
Hansa Biopharma to Participate in H.C. Wainwright 26th Annual Global Investment…
To learn more about Hansa Biopharma see the latest Corporate Presentation here. The latest investor presentation can be viewed here. To learn more about Hansa Biopharma see the latest Corporate Presentationhere. The latest investor presentation can be viewedhere. For more information: Evan Ballantyne,Chief Financial OfficerE:
[email protected]
Stephanie Kenney, VP Global Corporate Affairs E:
[email protected]
About Hansa Biopharma Hansa...
PR Newswire
05/09/2024
Exyte acquires TTP Group to accelerate growth of Biopharma and Life Sciences…
TTP executes a variety of projects, ranging from revamps of existing plants to the realization of future plants. The company has a strategic footprint in Europe and maintains a network of 27 locations in Austria, Belgium, France, Germany, and Switzerland. In 2023, about 1,000 employees[1] generated sales of some €170 million. In the coming years, TTP intends to continue the strong profitable growth of recent years. TTP executes a variety of projects, ranging from revamps of existing plants to...
PR Newswire
05/09/2024
Venus Medtech Venus-Vitae Completes First Two Implantations in SMART-ALIGN…
Following the first two successful implantations, Venus-Vitae SMART-ALIGN pivotal clinical trial will be progressively launched at around 20 centers in Europe, North America and China, enrolling a total of 150 patients. The trial data will be used to support registration applications in the EU, Canada, China and other territories. Following the first two successful implantations, Venus-Vitae SMART-ALIGN pivotal clinical trial will be progressively launched at around 20 centers inEurope,...
PR Newswire
05/09/2024
Altri Comunicati
